RaySearch Laboratories AB (OSTO:RAY B) ROCE % : 14.10% (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is RaySearch Laboratories AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. RaySearch Laboratories AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 14.10%.

RaySearch Laboratories AB ROCE % Historical Data

The historical data trend for RaySearch Laboratories AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RaySearch Laboratories AB ROCE % Chart

RaySearch Laboratories AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

8.28

-0.09

-5.05

3.56

9.52

RaySearch Laboratories AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															7.56	5.76	9.04	15.49	14.10

RaySearch Laboratories AB ROCE % Calculation

RaySearch Laboratories AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	119.775	/	( ( (1875.95 - 637.098)	+	(1952.666 - 675.049) )	/ 2 )
	=	119.775	/	( (1238.852	+	1277.617)	/ 2 )
	=	119.775	/	1258.2345
	=	9.52 %

RaySearch Laboratories AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	183.072	/	( ( (1952.666 - 675.049)	+	(2064.202 - 745.892) )	/ 2 )
	=	183.072	/	( ( 1277.617	+	1318.31 )	/ 2 )
	=	183.072	/	1297.9635
	=	14.10 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

RaySearch Laboratories AB (OSTO:RAY B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

RaySearch Laboratories AB ROCE % Related Terms

Thank you for viewing the detailed overview of RaySearch Laboratories AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

RaySearch Laboratories AB (OSTO:RAY B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » RaySearch Laboratories AB (OSTO:RAY B) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RSLBF:USA 0GRZ:UK 27R:Germany

Address

Sveavagen 44, P.O. Box 3297, Stockholm, SWE, 103 65

Website

https://www.raysearchlabs.com

RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for improved cancer treatment. The company develops and markets the RayStation* treatment planning system and RayCare* oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia, Europe and the rest of the world. The company generates majority of its sales from the North America.

RaySearch Laboratories AB (OSTO:RAY B) Headlines

No Headlines